Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00643578 · ClinicalTrials.gov registry record · NA

Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

A NA study, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
37
Enrollment target

NCT00643578: Completed NA study, sponsored by University of Florida.

NCT00643578 is a NA study that has completed, run by University of Florida. The registered enrollment target is 37 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00643578, a NA study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target

Study Summary

The purpose of this study is to find out whether a difference between two doses of formoterol can be detected by methacholine challenge.

Primary Outcome

The PC20 is the provocational dose of methacholine causing a 20% drop in forced expiratory volume in the first second.

Interventions

  • DRUG formoterol
  • DEVICE Dry Powder Inhaler (Twisthaler)

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2008-03
Est. Completion 2009-01
Phase NA
University of Florida

1,106 total trials

What the finished NCT00643578 record still lists

NCT00643578 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which formoterol is the first listed.

NCT00643578 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00643578 about?

NCT00643578 is a clinical study titled "Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay". The purpose of this study is to find out whether a difference between two doses of formoterol can be detected by methacholine challenge.

What is the current status of trial NCT00643578?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2008-03. Estimated completion is 2009-01.

What interventions are being tested in trial NCT00643578?

The interventions under investigation include: formoterol (DRUG), Dry Powder Inhaler (Twisthaler) (DEVICE).

Who is sponsoring clinical trial NCT00643578?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00643578's enrollment target sits among peer trials

37 1540th of 2000 higher than 460 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02800486 · 37 participants · Phase 2

    Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

  • NCT03173937 · 37 participants · Phase 1

    Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

  • NCT03295227 · 37 participants · Phase 1

    Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer

  • NCT03401047 · 37 participants · Early Phase 1

    Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00643578, the US trial registry maintained by the National Library of Medicine. NCT00643578 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.